Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
20 oct. 2022 08h00 HE
|
Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...
Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine
28 avr. 2022 08h00 HE
|
Mindera Health
San Diego, CA, April 28, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform - the first realization of precision medicine in psoriasis, has...
Mindera Health™ Appoints Ted St. Martin as Chief Financial Officer
10 mars 2022 08h00 HE
|
Mindera Health
San Diego, CA, March 10, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of precision medicine in psoriasis, ...
Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors
01 mars 2022 08h00 HE
|
Mindera Health
San Diego, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in...
Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients
04 janv. 2022 11h00 HE
|
Mindera Health
SAN DIEGO, CA and LAKELAND, FL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate...
Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies
16 nov. 2021 11h30 HE
|
Mindera Health
San Diego, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...
Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics
21 oct. 2021 12h00 HE
|
Mindera Health
San Diego, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...
Mindera Corporation Shifts Name to Mindera Health to Sharpen Focus on Its Personalized Medicine Platform
05 oct. 2021 11h00 HE
|
Mindera Health
San Diego, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mindera Corporation, developers of the groundbreaking Mind.Px™ - the first realization of truly personalized medicine in psoriasis - has changed its...